仟源醫藥(300254.SZ)：2019年淨利預降0%-30%
格隆匯1月23日丨仟源醫藥(300254.SZ)披露2019年度業績預告，公司預計2019年1-12月實現歸屬於上市公司股東的淨利潤506.88萬元-724.11萬元，同比下降0%-30%。業績變動原因説明：
1、根據國家醫療保障局、人力資源社會保障部2019年8月20日發佈的《國家基本醫療保險、工傷保險和生育保險藥品目錄》(醫保發【2019】46號)(以下簡稱“國家醫保目錄”)，公司主要產品美洛西林鈉舒巴坦鈉、阿莫西林鈉舒巴坦鈉退出了本次《國家醫保目錄》，上述產品2018年度銷售收入分別佔營業收入27.44%、3.47%，對公司影響較大。2019年4季度，受上述醫保目錄調整影響，公司上述產品營業收入同比下降較大。
2、報告期內，由於受我國出生人口持續下降、部分省份藥品招標降價、公司整體市場投入和產品推廣力度持續增強等因素的影響，子公司杭州保靈集團有限公司、浙江海力生製藥有限公司、杭州恩氏基因技術發展有限公司等存在商譽減值的跡象，公司根據評估機構對主要子公司商譽減值測試的初步結果計提了商譽減值準備。
3、報告期內，預計非經常性損益對淨利潤的影響約6,400萬元，其中收到各類政府補貼的影響約4,300萬元。此外，公司按權益法核算的聯營公司寧波磐霖仟源股權投資合夥企業(有限合夥)(以下簡稱“合夥企業”)對外投資了若干公司，該合夥企業對上述投資無控制、無共同控制、無重大影響，按成本法核算。報告期內，根據新金融工具準則的要求，公司對合夥企業的財務報表進行了調整，主要系根據評估機構的評估結果將合夥企業賬面的長期股權投資調整為以公允價值計量的其他非流動金融資產，並將報告期內上述其他非流動金融資產的公允價值變動計入報告期內的公允價值變動損益，導致公司按權益法核算的長期股權投資收益較上年出現大幅增長，並由此產生約1,650萬元的非經常性損益影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
